Authors

Dr. Lara reviews the evolving systemic therapy paradigm in renal cell carcinoma

“The question of who is a candidate for active surveillance is hard to answer because this is a bedside, gut decision," says Primo Nery Lara, Jr, MD.

Tips for optimizing productivity and collaboration for trainees who go unmatched in urology

"Going into the upcoming application cycle, I am now a bit more excited and a little less terrified," writes Leah Ashton, MD.

Leveraging technology to empower patients and reduce physician burnout

Implementing the right practice technology can not only mitigate physician burnout, it can also enable patients to take charge of their own care experience.

Expert shares best practices for keeping a medical office clean

Here are 5 best practices for cleaning a medical office.

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Artificial intelligence is the new ghost author in urological research

“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.

Exosome-based Genomic Testing improves Early Detection of Clinically Significant Prostate Cancer

Workplace violence in health care remains rampant as preventive efforts continue

Even before the pandemic, violence against health care workers was escalating.

Bridget Koontz, MD, on PSMA-PET’s impact on treatment planning

“For us, being able to know where the cancer is allows us to target it, and I think that lets us be much more effective with our treatment,” says Bridget F. Koontz, MD, FASTRO.

Is video-based research feasible for pediatric urology visits?

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.

FDA approves niraparib/abiraterone tablet for BRCA-positive mCRPC

The approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.

Better evidence for efficacy of postmenopausal incontinence treatments needed

Urinary symptoms were not significantly improved from local estrogen use in most studies, though an improvement in vaginal symptoms was observed.

Urologic research and COVID-19: Unmasking the silver lining

In this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.

ARV-766 shows promising efficacy and tolerability in mCRPC

Results presented from a phase 1/2 trial of ARV-766 demonstrated efficacy and tolerability in patients whose metastatic castration-resistant prostate cancer progressed after androgen receptor pathway inhibitor therapy.

Money Matters: Expert on why annuities are the “Swiss Army knife” of personal finance

Social Security benefits aren’t sufficient to fund retirement for most people. And given the aging of the population and projected trust-fund shortfall, they may be less generous in the future.

Perioperative cabozantinib shows promise in metastatic kidney cancer

Perioperative treatment with cabozantinib is feasible with early signs of clinical activity in patients with intermediate- and poor-risk metastatic renal cell carcinoma.

Assessing fit in urology residency through asynchronous video

A key finding was that among the qualities applicants highlighted, only “learning and growth” correlated with interview selection.

Race-based adjustment of eGFR: Current opinions and impact on urologic oncology

“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.

Despite overall gains, leadership and payment gaps remain for women in medicine

"The good news is that women have been entering medicine in increasing numbers for more than three decades. The not-so-good news is that women are still underrepresented and underutilized in positions of power," writes Deborah M. Shlian, MD, MBA.

Expert insight on ransomware: Is your practice prepared?

Ransomware has never been a more serious threat for health care organizations, even small medical practices.

How APPs can be involved with genitourinary cancer care

A nurse practitioner discusses how she supports multiple providers in a large academic practice.

Moving transperineal prostate biopsy into the clinic

Learning curve for technique is short, but capital expenditures are required.

Expert Opinion: We cannot continue to ignore the problem of physician mental distress

"We need health systems, state medical boards and physician employment settings to commit to prioritizing physician wellbeing and provide the reassurances and resources that encourage physicians in need to seek help," writes Russell Libby, MD.

Malpractice Consult: How likely are you to face a medical malpractice lawsuit?

"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.

US Chamber of Commerce asks for delay on non-compete rule

The request comes amid growing concerns about the rule’s implications for businesses and employees nationwide.

Theranostic therapies expand frontline use in prostate cancer

"It's been a very exciting time for the radioligand space," says J. Travis Mendel, MD.

Breakthrough Study in Image-Guided Prostate Cancer Treatment

Published OPTIMUM Trial results compares high-resolution micro-ultrasound with MRI when considering prostate biopsy.

MRI-based screening emerging as viable alternative to PSA testing

“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.

Is greater patient control of their personal health records a plus for physicians?

The Cures Act has teeth and consumers are becoming increasingly aware of their right to obtain their information.

DFS end point not reached with adjuvant nivolumab for locally advanced high-risk RCC

Patient subgroups that favored nivolumab vs placebo included patients with sarcomatoid features (HR, 0.42; 95% CI, 0.17-1.07), PD-L1 expression of 1% or greater (HR, 0.53; 95% CI, 0.22-1.29), and those with lower limit of normal hemoglobin at baseline (HR, 0.49; 95% CI, 0.25-1.49).